2EB0.F QUOIN PHARMACEUT.ADR5000
- Market cap
- EUR 14.3M
- P/E
- -
- P/B
- 4.28x
- ROE
- -527.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 2EB0.F undervalued?
Graham numberThe Graham number of QUOIN PHARMACEUT.ADR5000 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
QUOIN PHARMACEUT.ADR5000 fundamental analysis
No fundamental analysis for QUOIN PHARMACEUT.ADR5000 yet.
QUOIN PHARMACEUT.ADR5000 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About QUOIN PHARMACEUT.ADR5000
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, whic…
Full company profileQUOIN PHARMACEUT.ADR5000 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
QUOIN PHARMACEUT.ADR5000 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -6.06M | -9.26M | -9.38M | -9.53M | -16.3M | -21.2M |
| EBITDA | - | -8.56M | -9.27M | -9.43M | -16.2M | -21.1M |
| Net Income | -21.5M | -9.38M | -8.69M | -8.96M | -15.8M | -20.7M |
| EPS | -384 | -23 | -8.80 | -1.00 | -0.30 | -0.30 |
| Balance Sheet | ||||||
| Total Assets | 9.36M | 14.5M | 12.2M | 15.7M | 20.4M | 12.0M |
| Total Liabilities | 8.70M | 7.05M | 6.51M | 6.50M | 7.27M | 8.04M |
| Shareholders' Equity | 657K | 7.41M | 5.66M | 9.20M | 13.1M | 3.93M |
| Cash & Short-term Investments | 7.48M | 2.86M | 2.40M | 3.62M | 3.82M | 3.85M |
| Cash Flow | ||||||
| Operating Cash Flow | -5.72M | -8.48M | -7.86M | -7.86M | -13.5M | -16.0M |
| Capital Expenditure | 625K | 250K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -6.35M | -8.73M | -7.86M | -7.86M | -13.5M | -16.0M |
| Ratios | ||||||
| ROE | -3,266.6% | -126.7% | -153.4% | -97.4% | -120.5% | -527.3% |
| ROA | -229.4% | -64.9% | -71.4% | -57.1% | -77.5% | -173.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
QUOIN PHARMACEUT.ADR5000 dividends
QUOIN PHARMACEUT.ADR5000 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:12 on Jul 18, 2023.
Who owns QUOIN PHARMACEUT.ADR5000
- Insiders 3.67%
- Institutions 26.81%
- Public & others 69.52%
- Shares outstanding 4.80M
- Free float 4.63M
QUOIN PHARMACEUT.ADR5000 company profile
- Company name
- QUOIN PHARMACEUT.ADR5000
- Ticker
- 2EB0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- 42127 Pleasant Forest Court, Ashburn, VA, United States, 20148-7349
- Phone
- 703 980 4182
- Website
- quoinpharma.com
About QUOIN PHARMACEUT.ADR5000
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
QUOIN PHARMACEUT.ADR5000 management
3- Dr. Michael Myers Ph.D.Co-Founder, CEO & Chairman · born 1962
- Ms. Denise CarterCo-Founder, COO & Director · born 1969
- Ms. Sally LawlorChief Financial Officer · born 1983